HUP0300219A2 - Compositions and methods for l-nucleosides, l-nucleotides, and their analogs - Google Patents

Compositions and methods for l-nucleosides, l-nucleotides, and their analogs

Info

Publication number
HUP0300219A2
HUP0300219A2 HU0300219A HUP0300219A HUP0300219A2 HU P0300219 A2 HUP0300219 A2 HU P0300219A2 HU 0300219 A HU0300219 A HU 0300219A HU P0300219 A HUP0300219 A HU P0300219A HU P0300219 A2 HUP0300219 A2 HU P0300219A2
Authority
HU
Hungary
Prior art keywords
compounds
nucleosides
nucleotides
analogs
compositions
Prior art date
Application number
HU0300219A
Other languages
Hungarian (hu)
Inventor
Zhi Hong
Johnson Lau
Chin-Chung Lin
Ljubisa Rakic
Kanda Ramasamy
Robert Tam
Füsun Zeytin
Original Assignee
Icn Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.
Publication of HUP0300219A2 publication Critical patent/HUP0300219A2/en
Publication of HUP0300219A3 publication Critical patent/HUP0300219A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)

Abstract

Nukleozid- és nukleotidvegyületeket, és ezek analógjait/prodrogjaitismertetik. Különösen szóba jöhető vegyületek közé tartozik az 1-b-L-ribofuranozil-1,2,4-triazol-3-karbox-amid, amely módosítva és/vagyfoszforilezve lehet. A szóba jöhető vegyületeket továbbá egyébgyógyászatilag hatékony vegyületekkel kombinálhatják, különösenRibavirinnel, antitestekkel és citokinekkel. A szóba jöhető vegyületekelőnyösen például antivirális vegyületként, gyulladásgátlóvegyületként, daganatellenes vegyületként és sejtnövekedést stimulálóvegyületként alkalmazhatók. ÓNucleoside and nucleotide compounds and their analogues/prodrugs are described. Particularly suitable compounds include 1-b-L-ribofuranosyl-1,2,4-triazole-3-carboxamide, which may be modified and/or phosphorylated. The compounds in question can also be combined with other medically effective compounds, especially Ribavirin, antibodies and cytokines. The compounds in question can preferably be used, for example, as antiviral compounds, anti-inflammatory compounds, antitumor compounds and cell growth stimulating compounds. HE

HU0300219A 1999-12-23 2000-12-19 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs HUP0300219A3 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US17209799P 1999-12-23 1999-12-23
US17344699P 1999-12-29 1999-12-29
US17511100P 2000-01-06 2000-01-06
US19075800P 2000-03-20 2000-03-20
US22687500P 2000-08-22 2000-08-22
US22694700P 2000-08-22 2000-08-22
US23382300P 2000-09-19 2000-09-19
US23382100P 2000-09-19 2000-09-19
US23354800P 2000-09-19 2000-09-19
US23382200P 2000-09-19 2000-09-19
US23546500P 2000-09-26 2000-09-26
PCT/US2000/034605 WO2001045509A1 (en) 1999-12-23 2000-12-19 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs

Publications (2)

Publication Number Publication Date
HUP0300219A2 true HUP0300219A2 (en) 2003-06-28
HUP0300219A3 HUP0300219A3 (en) 2005-07-28

Family

ID=27582702

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300219A HUP0300219A3 (en) 1999-12-23 2000-12-19 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs

Country Status (20)

Country Link
EP (1) EP1244356A4 (en)
JP (1) JP2003523957A (en)
KR (1) KR20030032908A (en)
CN (1) CN1420723A (en)
AU (1) AU2442201A (en)
BR (1) BR0016162A (en)
CA (1) CA2384326A1 (en)
CZ (1) CZ20022112A3 (en)
HK (1) HK1049944A1 (en)
HR (1) HRP20020485A2 (en)
HU (1) HUP0300219A3 (en)
IL (1) IL148514A0 (en)
MX (1) MXPA02006251A (en)
NO (1) NO20022969D0 (en)
NZ (1) NZ517634A (en)
PL (1) PL364927A1 (en)
SI (1) SI20976A (en)
SK (1) SK8612002A3 (en)
WO (1) WO2001045509A1 (en)
YU (1) YU47802A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
CN1863812A (en) 2003-09-11 2006-11-15 弗·哈夫曼-拉罗切有限公司 Polymorphic antiviral nucleoside compounds
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
KR20090094800A (en) * 2006-09-11 2009-09-08 써던 리서취 인스티튜트 Azole nucleosides and use as inhibitors of rna and dna varial polymerases
CN102952104A (en) * 2011-08-17 2013-03-06 黑龙江省松花江药业有限公司 Furan compound
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN104387431A (en) * 2014-10-24 2015-03-04 江南大学 Preparation method of high-specificity ribavirin artificial antigens
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
CN111788196A (en) 2018-01-09 2020-10-16 配体药物公司 Acetal compounds and their therapeutic use
CN109528638B (en) * 2018-12-20 2021-07-06 江西润泽药业有限公司 Ribavirin derivative preparation and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
BR8607124A (en) * 1986-03-27 1988-04-05 Harry Edward Gruber A METHOD OF INCREASING ADENOSIN EXCRETION
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
ATE238328T1 (en) * 1996-10-16 2003-05-15 Ribapharm Inc MONOCYCLIC L-NUCLEOSIDES, ANALOGAS AND THEIR APPLICATIONS
TWI277424B (en) * 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
AU2026900A (en) * 1998-11-20 2000-06-13 Salk Institute For Biological Studies, The Neuron stimulation by ribavirin, and analogs thereof

Also Published As

Publication number Publication date
MXPA02006251A (en) 2003-01-28
YU47802A (en) 2006-03-03
CN1420723A (en) 2003-05-28
CA2384326A1 (en) 2001-06-28
WO2001045509A1 (en) 2001-06-28
SK8612002A3 (en) 2003-03-04
IL148514A0 (en) 2002-09-12
NO20022969L (en) 2002-06-20
SI20976A (en) 2003-02-28
NO20022969D0 (en) 2002-06-20
EP1244356A4 (en) 2003-03-19
AU2442201A (en) 2001-07-03
NZ517634A (en) 2004-06-25
JP2003523957A (en) 2003-08-12
EP1244356A1 (en) 2002-10-02
BR0016162A (en) 2002-08-13
HRP20020485A2 (en) 2005-10-31
PL364927A1 (en) 2004-12-27
KR20030032908A (en) 2003-04-26
HK1049944A1 (en) 2003-06-06
CZ20022112A3 (en) 2003-05-14
HUP0300219A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
AP1411A (en) Pyrrolo[2,3d] pyrimidine compositions and their use.
EP2955190A3 (en) Chemical compounds
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NO975585L (en) C-4 'modified adenosine kinase inhibitors
DE3854297D1 (en) NUCLEOSIDES AND NUCLEOTIDES WITH ANTIVIRAL, ANTITUMORAL, ANTIMETASTATIC AND IMMUNE-STIMULATING EFFECT.
DK1178999T3 (en) L-ribo-LNA analogues
WO2003062255A3 (en) Sugar modified nucleosides as viral replication inhibitors
HUP0300219A2 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
ATE154029T1 (en) 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES
TR199902994T2 (en) Systems that use expandable bodies to treat broken or diseased bone.
ATE133678T1 (en) 9-PURINYL PHOSPHONIC ACID DERIVATIVES
TR200200137T2 (en) Nucleotide analog compositions.
CA2347979A1 (en) Treatment of skin with adenosine or adenosine analog
HUP0103641A3 (en) Antiviral purine derivatives, pharmaceutical compositions containing them and their use
DK1280813T3 (en) Antiviral pyrimidine nucleoside analogues
NO20020931L (en) Pyrrolo [2,3-d] pyrimidine nucleoside analogs
EP3919501A4 (en) 5'-modified nucleoside and nucleotide using same
EP0334361A3 (en) Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
EP0749439A4 (en) Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof
ATE63556T1 (en) MACROLIDE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE.
ATE254126T1 (en) ANTIVIRAL NUCLEOSIDE ANALOGUES
GB9506644D0 (en) Preparation of nucleoside analogues
AU2003266081A1 (en) Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides